Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
about
MR Imaging Biomarkers in Oncology Clinical TrialsIntegrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma.Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.Commentary: Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy.Histogram analysis parameters of apparent diffusion coefficient reflect tumor cellularity and proliferation activity in head and neck squamous cell carcinoma.Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas
P2860
Q30364608-0C9566AB-0AB2-42F0-BA0C-84E364C37E03Q31113520-98593803-1EA1-4C78-A38E-0387A5E4D0F0Q35771783-99D0583A-38DF-41DA-8EA8-B6BF350D752EQ38747896-94D94EEA-A9CF-4CEA-8BA4-E4D9AD51A9B4Q38998271-FA447256-0472-4465-A59F-55F6943E1DE8Q39685607-765C4540-C0BF-42B7-8D57-A3A1890BE28CQ40938974-8E3D30C1-24E2-4E18-A430-6C96590D9390Q42702318-3DA11425-3273-4646-9539-909E428F8217Q49829484-0708C601-BA45-4EC1-99A1-40A84284C24EQ55040076-5FF9D9B0-129A-41D5-A2CF-6849D7709A95Q55690590-DACDCAB9-2781-460B-A010-484EA8E92769Q57177114-E261EC7F-943F-4A3E-9BDC-FB90B5072E84
P2860
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Comparison of ADC metrics and ...... ide, erlotinib and bevacizumab
@ast
Comparison of ADC metrics and ...... ide, erlotinib and bevacizumab
@en
type
label
Comparison of ADC metrics and ...... ide, erlotinib and bevacizumab
@ast
Comparison of ADC metrics and ...... ide, erlotinib and bevacizumab
@en
prefLabel
Comparison of ADC metrics and ...... ide, erlotinib and bevacizumab
@ast
Comparison of ADC metrics and ...... ide, erlotinib and bevacizumab
@en
P2093
P2860
P1476
Comparison of ADC metrics and ...... ide, erlotinib and bevacizumab
@en
P2093
Annette M Molinaro
Janine M Lupo
Jennifer Clarke
Laleh Jalilian
Michael Prados
Qiuting Wen
Sarah J Nelson
Susan M Chang
P2860
P2888
P304
P356
10.1007/S11060-014-1636-6
P577
2014-10-29T00:00:00Z